secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0000200406-23-000094
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation
---------------------------------------------------------------------------

- Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).
- Innovative Medicine revenue $13.89B (+5.1% reported); MedTech $7.46B (+10.0%).
- U.S. sales grew 11.1% to $11.996B; international sales rose 1.6% to $9.355B.
- Discontinued ops net earnings $21.7B (incl. gain from Kenvue separation) vs $148M prior year.
- Adjusted pretax income from continuing ops $8.03B, up 13.8% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/0000200406-23-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/jnj-20231017.htm
  HTML page:      https://secwatch.observer/filing/0000200406-23-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer